The variance that operating partners notice first
Two comparable locations. Comparable markets, comparable clinical teams, comparable competitive environments. One reaches full EBITDA contribution in 10 months. The other is still below the model at 18. When operating partners ask why, the answer is rarely market conditions. It is almost always marketing infrastructure – specifically, whether a systematic, pre-defined launch program existed to build the patient acquisition pipeline before opening day.
The frustrating thing about this variance is that it is largely preventable. Market conditions influence De Novo performance, but they explain far less variance than most platform leadership teams assume. The more important variable – the one within your control – is whether your marketing infrastructure gives every new location the same systematic launch advantage. When it does, performance converges. When it doesn’t, variance widens and gets misattributed to the market.
The Healthcare marketing Infrastructure gaps that actually drive the variance
The gaps with the highest impact on ramp performance are also the ones most commonly skipped under operational pressure – and they compound each other.
The most consequential gap is the absence of pre-opening marketing activity entirely – locations that launch with no patient acquisition pipeline, no pre-registered appointments, and no established digital presence. These locations spend their entire months-four-through-nine window building from zero while their ramp model assumed they’d be converting from a running start. The second most consequential gap is attribution infrastructure: without call tracking, campaign-level conversion data, and CRM integration in place before the first dollar is spent, you cannot tell what is working during the critical early months and cannot optimize in real time. A slow ramp without attribution data is a slow ramp with no clear path to acceleration.
The gaps that compound the first two are digital infrastructure shortfalls – a Google Business Profile claimed late, a location web page without local SEO, slow review velocity in the first 90 days. Each of these individually produces a manageable disadvantage. Together, they create a location that is invisible in local search during the months when organic discovery matters most and paid acquisition costs are highest. The final gap is the one that shows up last: no retention sequence for first-visit patients in the first 60 days, which allows the early patient relationships the opening push generated to lapse before they establish reappointment behavior.
Auditing your launch process: The questions that reveal the gaps
Pull the opening record for your last three to five locations and ask four questions: at what point did marketing activity begin relative to opening day? What was in place digitally on day one? Were there pre-registered appointments on the calendar before the first patient was officially seen? Was attribution infrastructure active before the first campaign dollar was spent?
A launch system produces documented, consistent answers across all five locations. A launch habit produces answers that vary – some locations had pre-registration, some didn’t; some had attribution from day one, some built it in month three. That variance in your launch process is almost always a leading indicator of the variance in your ramp performance.
Reverse-engineering your best launch to build the template
If you have a location that ramped in 10 months while comparable locations took 16 to 18, that location is the most valuable diagnostic in your portfolio. The question is whether you know specifically what marketing activity was in place that the underperforming locations were missing – the timing, the channels, the offers, the pre-registration approach, the conversion infrastructure, the review seeding process.
Most platforms don’t have a clean answer to that question, because the top-performing launch was executed well but not documented. The team that ran it moved to the next opening. The institutional knowledge walked out with them. Standardizing top-performing launch performance means going back to that location – or to the agency that ran it – and reconstructing what was actually in place, then codifying it into a playbook specific enough to be executed consistently by a different team in a different market without recreating the conditions from scratch. The test for “specific enough”: if a new regional marketing manager could run the first 90 days without asking for clarification on any major decision, it passes. If it requires institutional knowledge to interpret, it will produce institutional variance.
The answer that wins the operating partner conversation
Your operating partners will eventually ask: What is our modeled ramp timeline, and how often do we hit it? For most CMOs, this question is uncomfortable – because the honest answer involves variance that is hard to explain cleanly. The response that changes the conversation is not a defense of the variance. It is data that shows the variance is not random.
Specifically, locations that received the full pre-opening launch program consistently hit the modeled ramp timeline. Locations that received a compressed or partial launch program consistently ran behind it. That correlation, tracked across enough openings, converts the launch program from a discretionary cost to a documented IRR lever.
The math makes the case faster than any marketing argument. A location running six months behind the ramp model on a $2M EBITDA target represents roughly $1M in delayed contribution. If a full launch program costs $80K to $120K to execute, the question for the operating partner is not whether to fund it – it is why they would accept a seven-figure ramp penalty to save five figures in marketing spend. Framed that way, the conversation stops being about marketing budgets and starts being about portfolio yield.
Building that data set requires tracking launch program completeness alongside ramp performance across every new opening. You cannot make the argument retrospectively if you don’t know what was and wasn’t in place at each opening – which is another reason the audit is where this work starts.
“De Novo variance is not a market problem – it is a system problem. The platforms that prove it with data stop having budget conversations and start having investment conversations.”
Agency Creative builds standardized De Novo launch systems for PE-backed multi-site healthcare platforms – and helps CMOs build the data record that makes the case for marketing investment at every future opening. Let’s talk about what consistent ramp performance looks like in your portfolio.
Learn how Agency Creative can help boost your brand by calling us at 972.488.1660 or by contacting us online.
See More Work
